FindTrial
Sign In

Effectiveness and safety of updosing of Bilastine in uncontrolled chronic spontaneous urticaria

Effectiveness, safety and tolerability of standard dose of Bilastine and updosed Bilastine for the treatment of uncontrolled chronic spontaneous urticaria

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/08/035626
Enrollment
35
Registered
2021-08-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: Bilastine: Dose: 20 mg tablet once a day 1 hour before food Route:oral Duration :2 weeks Those not controlled,20 mg tablet twice daily 1 hour before food Duration :2 weeks Those not

Sponsors

Dr Sankha Subhra Chakraborty
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: INCLUSION CRITERIA: Male or female patients 18-65 years (both inclusive) Patients having uncontrolled chronic spontaneous urticaria UAS score>=7(urticaria activity score ),after being treated with H1 antihistamine in standard dose(other than BILASTINE).

Exclusion criteria

Exclusion criteria: Acute urticria, Physical urticaria, chronic Inducible urticaria,contact urticaria Systemic diseases and infections Herediary angioedema,atopic dermatitis Preganancy and lactation Known hypersensivity to Bilastine Corticosteroid use (systemic/topical) in recent times for same condition

Design outcomes

Primary

MeasureTime frame
urticaria activity score 3 denotes clinical efficacyTimepoint: 2 weekly interval wach incremental updosing—

Secondary

MeasureTime frame
safety and tolerabilty of updosing to be evauated using biochemical and pathological parametersTimepoint: 2 weekly—

Countries

India

Contacts

Public ContactDR SANKHA SUBHRA CHAKRABORTY

College of Medicine and Sagore Dutta Hospitalital

drdasmanisha@gmail.com9051663525

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026